MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keaf190

Медицинская библиотека · Rheumatology (Oxford, England) · 2025

A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review.

Haase Isabell, Richter Johanna, Holzer Marie-Therese, Fehse Boris, Ruffer Nikolas, Seibel Johan, Berger Susanna C, Gagelmann Nico, Borie Dominic, Ayuk Francis, Kötter Ina, Krusche Martin, Kröger Nicolaus

СтатьяКлинический случайОбзорПеревод в очереди

Аннотация

OBJECTIVES

To explore efficacy and safety of CD19-directed Chimeric Antigen Receptor (CAR) T cell therapy in a patient with Jo1-Antisynthetase-syndrome refractory to multiple immunosuppressants, including anti-CD38 therapy, and review published cases on CAR T cell therapy in idiopathic inflammatory myopathies (IIM).

METHODS

Following lymphodepletion, the patient received a single infusion of autologous CD19-directed CAR T cells. Clinical, serologic, and safety outcomes were monitored over 6 months. A literature review analysed prior cases for patient characteristics, outcomes, and adverse events.

RESULTS

CAR T cell therapy was well tolerated, with only low-grade cytokine release syndrome (CRS) and no neurotoxicity. Clinical assessments demonstrated significant and rapid improvement in muscle strength, arthritis, and pulmonary function, alongside normalization of muscle enzymes and inflammatory markers. Autoantibody levels remained unchanged. Transient skin alterations resolved with low-dose glucocorticoids. CAR T cells persisted for 3 months, followed by B cell reconstitution without disease relapse. The patient remains in remission on low-dose prednisolone at 6 months. Eight previously published cases of CAR T cell therapy in IIM consistently report significant improvement, with most patients stable off immunosuppressive therapy. Hypogammaglobulinemia was frequent, but no high-grade CRS, immune-effector-cell associated neurotoxicity syndrome (ICANS) or serious infections were reported.

CONCLUSION

CD19-directed CAR T cell therapy shows promise in refractory IIM, offering sustained clinical improvement and a favourable safety profile. The nine reported cases collectively highlight the potential of CAR T cell therapy even in patients with insufficient response to B cell/plasma-cell depleting therapies. Larger studies are needed to evaluate long-term efficacy, safety, and underlying mechanisms of CAR T cell therapy in refractory IIM.

Для цитирования: Haase Isabell, Richter Johanna, Holzer Marie-Therese, Fehse Boris, Ruffer Nikolas, Seibel Johan, Berger Susanna C, Gagelmann Nico, Borie Dominic, Ayuk Francis, Kötter Ina, Krusche Martin, Kröger Nicolaus. A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review.. Rheumatology (Oxford, England). 2025. DOI: 10.1093/rheumatology/keaf190.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.